Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxSys Synergy
- Development stage
- Preclinical
- Lead developer
- Angiotech Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Implant
01
Overview
VaxSys Synergy is a proprietary vaccine stabilization platform and a line of thermostable vaccine products developed by VaxSys, LLC. The technology utilizes a unique formulation matrix to render vaccines, most notably the Inactivated Polio Vaccine (IPV), resistant to degradation caused by temperature fluctuations, including extreme heat and freezing. By eliminating the need for a continuous 2–8°C cold chain, VaxSys Synergy aims to improve vaccine accessibility and reduce wastage in low-resource settings and remote geographic areas. The lead application, Synergy-sIPV, is a stabilized trivalent inactivated polio vaccine designed to support global eradication efforts by providing a product that remains potent under ambient conditions. The platform's mechanism involves the physical stabilization of viral antigens, preserving their structural integrity and immunogenicity during storage and transport.
- Brand names
- Synergy
- Other names
- VaxSys Stabilized IPVSynergy Stabilized Vaccine
Beyond the preview
Go deeper on VaxSys Synergy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VaxSys Synergy.